A team of biochemists at the University of California, Santa Cruz, has developed a faster way to identify molecules in the ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...

More than 100 million people in the United States suffer from metabolic dysfunction-associated steatotic liver disease (MASLD ...

Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...

Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...

Researchers from The Ohio State University and the Indian Institute of Technology Madras have developed an artificial intelligence framework to rapidly generate drug-like molecules that are easier to ...

An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how antibody medicines are tested and brought to patients. The work, published ...

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and ...

February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced ...

DUBAI, 8th February, 2026 (WAM) -- The Emirates Drug Establishment (EDE) is all set to participate in the World Health Expo 2026 (WHX), taking place at Expo City Dubai, where it will be showcasing a ...

Despite efforts led by the National Agency for Food and Drug Administration and Control (NAFDAC) and the Standards ...